Methylphenidate eases depressive symptoms in palliative care, meta-analysis finds, though evidence remains uncertain

A systematic review and meta-analysis pooled five randomised controlled trials (342 participants) comparing methylphenidate-based interventions against placebo, usual care or background antidepressants for depressive symptoms in adults with advanced, life-limiting illness receiving palliative care. Methylphenidate was associated with greater overall improvement in depressive symptoms (standardised mean difference −0.47, 95% CI −0.81 to −0.13) and a higher rate of depression response (risk ratio 1.78, 95% CI 1.09–2.89). Depression-targeted and fatigue-focused trials did not differ significantly from one another. Meta-analysis Risk of bias was low in only one of the five trials, and the review authors rate overall certainty of evidence as very low to low, citing small samples, heterogeneity and indirectness — several trials measured depression only as a secondary outcome to fatigue.

Conventional antidepressants are limited in palliative care by a delayed onset that is a poor match for patients with a short prognosis; methylphenidate’s faster action is the clinical rationale for interest in it. This evidence supports methylphenidate as a plausible, cautious, individualised option in that specific circumstance — not as an established alternative to conventional antidepressant treatment, and not as a basis for a protocol-level change in first-line prescribing. The review authors themselves call for adequately powered trials with depression as the primary endpoint before the case can be considered settled.